More Cynata Therapeutics Limited news
Cynata Therapeutics LimitedASX: CYP

Further data supports potency of Cynata MSCs

Jun 13, 2022 at 11:32 PM EDT · Issued by Cynata Therapeutics Limited

Filed with ASX · Jun 13, 2022 at 11:32 PM EDT

On 6ix: 6ix.com/news/further-data-supports-potency-of-cynata-mscs

Cynata Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Cynata Therapeutics Limited on 6ix

Story so far

  • Cynata MSCs beneficial in preclinical ARDS studyApr 17, 2020

Earlier from Cynata Therapeutics

  • FDA Clears Cynata IND for Phase 2 Trial in GvHDMay 26, 2022
  • Notice of Allowance for Cynata Chinese PatentFeb 27, 2022
  • Cynata Receives Decision to Grant a Patent in JapanJan 26, 2022
  • FUJIFILM Cellular Dynamics Executes Manufacturing AgreementDec 28, 2021
  • Cynata Commences DFU Clinical TrialDec 21, 2021

Later from Cynata Therapeutics

  • Pipeline Update Following Strategic Portfolio ReviewAug 11, 2022
  • Grant Award to Fund Study of Cynata MSCs in Heart DiseaseSep 25, 2022
  • Successful Completion of Planned DSMB Review of DFU TrialOct 11, 2022
  • Notice of Allowance for Australia & Canada Cymerus PatentsOct 16, 2022
  • New Kidney Transplantation Clinical Trial for Cynata & LUMCNov 1, 2022
All Cynata Therapeutics news releases↗

Follow Cynata Therapeutics into a list and get an email when it puts out news.

Follow Cynata Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer